ATLAS ACS2-TIMI 51

ATLAS ACS 2-TIMI 51 was a phase III, multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating an oral, direct factor Xa inhibitor (rivaroxaban) in subjects following an acute coronary syndrome. Subjects received low-dose aspirin therapy (75 to 100 mg/day), and enrollment was stratified based upon the intent of the investigator to administer a thienopyridine [Stratum 1 (aspirin only) and Stratum 2 (aspirin plus a thienopyridine)]. Two different doses of rivaroxaban were tested: 2.5 mg twice a day and 5.0 mg twice a day.

PRESENTATIONS

TIMI 51 Slides
Atlas ACS2-TIMI 51 Poster (Alkhalfan AHA 2019)

PUBLICATIONS

Relation of White Blood Cell Count to Bleeding and Ischemic Events in Patients With Acute Coronary Syndrome (from the ATLAS ACS 2-TIMI 51 Trial)

The Association of White Blood Cell Count and Bleeding in Acute Coronary Syndrome: An Insight Into the Atlas ACS-TIMI 51 Trial

Rivaroxaban and Post-Stroke Neurological Outcomes in Patients With Acute Coronary Syndrome

D-Dimer Levels and Effect of Rivaroxaban on Those Levels and Outcomes in Patients With Acute Coronary Syndrome (An ATLAS ACS-TIMI 46 Trial Substudy)

Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial

The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 – TIMI 51 trial

The Role of Rivaroxaban in Atrial Fibrillation and Acute Coronary Syndromes

The Efficacy and Safety of Low-Dose Rivaroxaban With or Without a Proton Pump Inhibitor: Insights From the ATLAS ACS 2-TIMI 51 Trial

Rivaroxaban in the Setting of Continued Dual Antiplatelet Therapy: Findings from the ATLAS ACS 2 – TIMI 51 Trial

Comparison of the Efficacy and Safety of Two Rivaroxaban Doses in Acute Coronary Syndrome (from ATLAS ACS 2-TIMI 51)

Rivaroxaban in Patients Stabilized after a ST-Elevation Myocardial Infarction: Results from the ATLAS ACS 2-TIMI 51 Trial

Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51

Rivaroxaban Reduces Spontaneous and Large Myocardial Infarctions: findings from the ATLAS ACS 2 – TIMI 51 Trial

Evaluation of Cardiac Events in ATLAS ACS 2-TIMI 51

Rivaroxaban in patients with a recent acute coronary syndrome

A Net Clinical Outcome Analysis Comparing Fatal or Irreversible Ischemic and Bleeding Events in ATLAS ACS 2 – TIMI 51

Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome

 

 

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close